Thirona

Name

Thirona

Legal name

Thirona B.V.

Website

https://thirona.eu

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Medical Imaging AI Software

NAICS

Software Publishers (5132)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Imaging Informatics & Workflow (PACS/RIS/VNA) (HLAHABAI), Lung Cancer Screening & Pulmonary Nodule Clinic (HLAKANAI)

Keywords

• AI lung image analysis
• Thoracic CT quantification
• Pulmonary intervention software
• Clinical trial imaging
• Medical imaging AI

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Drug Development Services: Quantitative CT analysis and treatment efficacy assessment for imaging-based respiratory clinical trials serving pharmaceutical companies developing novel therapies.
2. Pulmonary Interventions Technology: AI-enabled imaging technology licensing for next-generation bronchoscopic and surgical procedures serving MedTech companies.
3. LungQ Software Platform: AI-powered lung image analysis software offered as clinical software with regulatory clearance (FDA 510(k), CE certified) for clinical use and clinical research.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Thirona develops and sells AI-powered software for quantitative analysis of lung CT images, centered on its modular LungQ platform that performs advanced anatomical segmentation, disease quantification, and bronchoscopy pathway planning. The software supports pharmaceutical companies running imaging-based respiratory clinical trials, MedTech firms developing pulmonary interventions, and hospitals delivering clinical care for COPD, cystic fibrosis, severe asthma, bronchiectasis, and pulmonary hypertension.

Product overview

Thirona offers a modular AI-powered product portfolio centered on its LungQ® platform for thoracic medical image analysis. LungQ® is a comprehensive technology portfolio of advanced deep-learning algorithms providing market-unique segmentation and quantification capabilities for chest CT scans. The platform is built as a modular architecture with specialized analysis modules including LungQ® BA (Bronchus-Artery Analysis), LungQ® VERA (Ventilation Estimation), LungQ® AVX (Artery Vein Phenotyping), LungQ® PXT (Perfusion Defect), LungQ® MP (Mucus Plugs Analysis), and LungQ® Navia (Bronchoscopy Pathway Planning). Thirona also offers CAD4COVID-CT and CAD4COVID-XRay for COVID-19 analysis, and previously offered CAD4TB for tuberculosis screening and RetCAD™ for retinal analysis (spun off in 2024). The products support pharmaceutical drug development, pulmonary interventions, and clinical care across therapeutic areas including COPD, bronchiectasis, severe asthma, cystic fibrosis, and pulmonary hypertension.

Differentiator

Problem solved

Functional benefit

Brands

• LungQ: AI-powered lung image analysis platform offering advanced segmentation and quantification capabilities for thoracic CT scan analysis, supporting drug development and pulmonary interventions
• RetCAD
• CAD4COVID
• CAD4TB

Products and services

• LungQ Modular AI-powered software platform for thoracic CT image analysis that delivers advanced deep-learning segmentation and quantification of lung anatomy and diseased lung regions for pharmaceutical drug development, MedTech intervention planning, and clinical care.
• CAD4COVID-CT AI software for automated analysis of COVID-19 on CT scans, providing standardized measurement of pulmonary involvement and severity assessment based on percentage of affected lung area; CE certified and FDA authorized.
• CAD4COVID-XRay AI tool for triaging suspected COVID-19 cases by analyzing chest X-rays, CE certified, and performing comparably to radiologists in triaging suspected COVID-19 cases.
• CAD4TB AI-based tuberculosis detection solution for chest X-ray analysis, used to screen large populations for tuberculosis across multiple countries.

Quantifiable outcome

• AI-enabled analysis detects subtle structural changes in airways that visual reads cannot identify
• +3 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature8 records

Partnerships

14 partnerships are on record, tiered core and minor.

• BlackfordcoreChannel Partner/ Reseller/ Distributor · 20 August 2024Commercial partnership to bring LungQ solution to healthcare professionals via the Blackford Platform, expanding distribution reach.
• VoiantcoreChannel Partner/ Reseller/ Distributor · 20 August 2024Global commercial partnership for full scope integral services for clinical trials with AI-powered lung image analysis, building on several years of fruitful cooperation.
• AidenceminorStrategic or Co-development Partner · 19 February 2024Joint clinical solution with Aidence and Incepto to support expansion of lung cancer screening in Europe with AI-powered software package.
• InceptominorStrategic or Co-development Partner · 19 February 2024Joint clinical solution with Aidence and Thirona for lung cancer screening and emphysema analysis, bringing AI into hospitals through integration partnerships.
• MedicalVRminorStrategic or Co-development PartnerCollaboration to integrate Thirona's chest CT analysis software into the PulmoVR virtual reality application for pre-operative planning of segmentectomy.
• Erasmus Medical CentercoreStrategic or Co-development PartnerPilot study collaboration with Cardio-thoracic Surgery department using virtual reality for complex lung surgery preparation, demonstrating 40% change in surgical strategy after VR review.
• COPDGene StudycoreStrategic or Co-development PartnerResearch partner for imaging arm of the study providing AI-based quantitative CT scan analysis (emphysema quantification, airway measurements) for over 10,000 participants.
• OSIC (Open Source Imaging Consortium)coreStrategic or Co-development PartnerGlobal consortium bringing together radiologists, clinicians, computational scientists, and industry leaders to develop respiratory digital imaging biomarkers using the world's largest clinical imaging database.
• European Bronchiectasis Registry (EMBARC)coreStrategic or Co-development PartnerCollaborative European research partnership applying AI-powered lung image analysis to enable deeper insights and comprehensive understanding of bronchiectasis disease mechanisms, analyzing over 600 CT scans.
• European Cystic Fibrosis Society Patient Registry / ENRICH ProjectcoreStrategic or Co-development PartnerEuropean initiative to standardize QCT metrics in CF population data, analyzing up to 10,000 CT scans from over 3,000 patients across 12 countries and 20 CF centers.
• CHU LiègeminorStrategic or Co-development PartnerResearch collaboration using LungQ AVX for artery-vein phenotyping in studies of pulmonary vascular diseases and pulmonary hypertension with Prof. Julien Guiot's team.
• CHU MontpellierminorStrategic or Co-development PartnerResearch collaboration using AI-driven quantitative CT analysis for studying biologic treatment effects in severe asthma patients with Prof. Arnaud Bourdin's team.
• DRAGON Project ConsortiumminorStrategic or Co-development PartnerPublic-private consortium investigating risk factors for developing lung damage and chronic complaints after COVID-19, developing decision support system for precise COVID-19 diagnosis using CT scanning.
• RetCAD Business Spin-outminorOthersThirona spun out its Retina business as of January 1st to pursue long-term growth plans for the RetCAD product line.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Siemens Healthineers (AI-Rad Companion): Siemens Healthineers' AI-Rad Companion offers AI-driven chest CT analysis embedded in the broader Siemens imaging ecosystem. It is a broad incumbent competitor with deep hospital integration and CT scanner footprint.
• Philips (IntelliSpace AI): Philips offers enterprise imaging AI through IntelliSpace AI and is also a Thirona integration partner. As a broad incumbent, it competes and partners simultaneously with Thirona in the lung imaging space.
• Aidoc: Aidoc is a leading AI imaging vendor offering a broad suite of triage and workflow algorithms across multiple modalities, including chest. It overlaps with Thirona on chest CT and operates as a broader, well-funded incumbent.

Direct peers

• icometrix: icometrix provides quantitative imaging AI biomarkers for clinical care and clinical trials; while focused on neuroimaging, it competes for pharma quantitative-imaging-endpoint budgets and uses similar regulatory and distribution models.
• Quibim: Quibim provides AI-based medical image analysis with a focus on oncology and quantitative imaging biomarkers. It competes with Thirona for pharma/CRO quantitative imaging endpoints in clinical trials.
• Annalise.ai: Annalise.ai offers comprehensive radiology AI including chest CT/X-ray modules covering pulmonary findings. It is a direct competitor in AI chest imaging for clinical reporting and triage.
• Aidence: Aidence is a European AI medical imaging company focused on lung cancer screening and pulmonary nodule detection on chest CT. It directly overlaps with Thirona's LungQ on lung CT analysis and is even a co-development partner on a joint lung-cancer screening solution with Incepto.
• Arterys: Arterys offers cloud-native AI imaging platforms including chest and cardiac analysis, and competes in the enterprise imaging AI space with Thirona for hospital and clinical-trial deployments.
• Riverain Technologies: Riverain Technologies (ClearRead) provides AI-driven chest CT and X-ray analysis for lung nodule detection and thoracic imaging workflow. It competes head-to-head with Thirona in AI lung image analysis for hospitals and clinical use.

Others

• Incepto: Incepto is a European AI imaging platform/distributor that aggregates third-party algorithms (including Thirona's via a joint lung-cancer screening offering). It is an adjacent channel/distribution player rather than a direct technology competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/thisisthirona
• YouTubeyoutube.com/@thirona4003
• LinkedInlinkedin.com/company/thirona

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Thirona